Globe Newswire (Wed, 10-Dec 8:00 AM ET)
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 13-Nov 4:01 PM ET)
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
Globe Newswire (Wed, 5-Nov 8:00 AM ET)
NUC-7738 Shows Promising Synergy With PD-1 Inhibitors in New Organoid Data From NuCana
Market Chameleon (Mon, 20-Oct 3:07 AM ET)
Globe Newswire (Sat, 18-Oct 8:00 AM ET)
Market Chameleon (Tue, 14-Oct 5:50 AM ET)
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
Globe Newswire (Tue, 14-Oct 8:00 AM ET)
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Nucana PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol NCNA.
As of December 31, 2025, NCNA stock price climbed to $3.60 with 51,343 million shares trading.
NCNA has a beta of -2.35, meaning it tends to be less sensitive to market movements. NCNA has a correlation of 0.00 to the broad based SPY ETF.
NCNA has a market cap of $1.37 billion. This is considered a Small Cap stock.
In the last 3 years, NCNA traded as high as $431,600.00 and as low as $2.78.
NCNA has underperformed the market in the last year with a return of -100.0%, while the SPY ETF gained +17.2%. In the last 3 month period, NCNA fell short of the market, returning -22.4%, while SPY returned +2.7%. However, in the most recent 2 weeks NCNA has outperformed the stock market by returning +1.1%, while SPY returned +0.7%.
NCNA support price is $3.35 and resistance is $3.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NCNA shares will trade within this expected range on the day.